Company: INDP
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001493152-25-021759
Chunk: 3

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-11-12
Form: 10-Q
Item: Part I, Item 1
Chunk 3
---
38,064 
  
    Net loss 
     -  
     -  
     -  
     (4,015,267) 
     (4,015,267)

    Balance, June 30, 2024 
     305,462  
    3,054  
    59,402,254  
    (53,239,100) 
    6,166,208 

    Stock-based compensation 
     -  
     -  
     444,184  
     -  
     444,184 
  
    Issuance of shares of common stock and warrants, net of issuance costs 
     58,708  
     587  
     2,461,383  
     -  
     2,461,970 
  
    Net loss 
     -  
     -  
     -  
     (3,069,036) 
     (3,069,036)
  
    Balance, September 30, 2024 
     364,170  
    $3,641  
    $62,307,821  
    $(56,308,136) 
    $6,003,326 

    Balance, January 1, 2025 
     428,799  
    $4,288  
    $64,379,770  
    $(60,439,183) 
    $3,944,875 
  
    Stock-based compensation 
     -  
     -  
     240,891  
     -  
     240,891 
  
    Issuance of shares of common stock and warrants, net of issuance costs (Note 6b) 
     75,335  
     754  
     1,985,990  
     -  
     1,986,744 
  
    Issuance of shares of common stock, net of issuance costs (Note 6c) 
     57,328  
     573  
     1,159,078  
     -  
     1,159,651 
  
    Issuance of commitment shares (Note 6c) 
     10,927  
     109  
     (109) 
     -  
     -